Summary
A bioRxiv preprint maps the maturation of human choroid-plexus organoids and reports that their response to valproic acid depends on developmental stage. Early changes recovered after the drug was withdrawn, while some late-stage transporter impairments persisted.
A bioRxiv preprint reports that human choroid-plexus organoids progress through a sequence of developmental changes to a molecular state with features of adult tissue. The researchers also found that recovery from valproic acid exposure differed by developmental stage in the organoids: some early effects reversed after the drug was removed, while certain late-stage transporter impairments persisted.
Mapping the organoids’ development
The choroid plexus (ChP) produces cerebrospinal fluid (CSF) and forms the blood-CSF barrier, which regulates exchange between blood and the fluid surrounding the brain and spinal cord. How the human ChP develops and matures has been difficult to study directly. Organoids—laboratory-grown models of tissue—offer a way to follow some of these processes over time.
The team built a single-cell RNA sequencing atlas across 15 time points and benchmarked it against human ChP tissue. The analysis showed an ordered progression: cells exited the cell cycle, developed cilia, and began expressing ion transporters. The sequence culminated in a transcriptional state with features of adult human ChP. The authors describe this as the first in-vitro ChP model to reach postnatal-like developmental milestones.
The researchers also used proteomics focused on centrosomes, cell structures involved in organizing cilia. They identified previously uncharacterised regulators associated with ciliogenesis at particular stages. This points to molecular components that may help explain how the organoid’s ciliated cells develop.
Drug exposure produced stage-dependent effects
To examine developmental plasticity—the capacity of a developing system to recover after disruption—the team exposed the organoids to valproic acid (VPA), a clinically used antiepileptic that the authors describe as an established teratogen. Early exposure disrupted multiciliogenesis, the formation of cells bearing multiple cilia, and secretion. These effects recovered after VPA was withdrawn.
When exposure occurred later, washing out the drug did not reverse the reported impairment of mature transporters. The contrast suggests that the capacity for recovery in this model depends on developmental stage and on the process being measured. It points to a narrowing window for recovery in some of the studied functions, rather than establishing a single point at which all developmental plasticity ends.
What the findings can tell us
The atlas provides a framework for studying human ChP maturation in the laboratory, while the exposure experiment shows how the timing of a perturbation can matter within that model. The results are from organoids, not a clinical study of people exposed to VPA, so they do not determine human pregnancy outcomes or quantify clinical risk. The work is a preprint and has not yet undergone peer review.